{"id":51863,"name":"AMRYT PHARMA","slug":"amryt-pharma","state":"MA","country":"United States of America","description":"pharmaceutical company","totalSpending":150000,"filings":5,"yearlySpending":[{"year":2022,"income":120000},{"year":2023,"income":30000}],"issues":[{"code":"HCR","display":"Health Issues"}],"firms":["AMRYT PHARMA"],"lobbyists":["LISA NELSON"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Patient access to medicines, Innovation (FDA), Pricing and Reimbursement","The FDA user fee reauthorization, and issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).","The FDA user fee reauthorization, and issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).","Issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).","Issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472)."]}